Shopping Cart
- Remove All
Your shopping cart is currently empty
BMS-695735, a benzimidazole inhibitor of insulin-like growth factor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water solubility, and high plasma protein binding.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,970 | 8-10 weeks | |
| 50 mg | $2,580 | 8-10 weeks | |
| 100 mg | $3,400 | 8-10 weeks |
| Description | BMS-695735, a benzimidazole inhibitor of insulin-like growth factor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water solubility, and high plasma protein binding. |
| Synonyms | DNC008930, CHEMBL459729, BMS695735, BMS 695735, BDBM27888 |
| Molecular Weight | 512.02 |
| Formula | C26H31ClFN7O |
| Cas No. | 1054315-48-8 |
| Relative Density. | 1.41 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.